#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3128	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2379	381.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1661	1661	C	426	C	373	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4764	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3993	356.5	0	.	n	.	0	T695C	SNP	695	695	T	1200	1200	C	361	C	331	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4764	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3993	356.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1842	1842	A	443	A,G	407,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4764	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3993	356.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2476	2476	C	402	C	369	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4764	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3993	356.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2550	2550	A	410	A	384	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4764	23S	2890	2890	99.9	23S.l6.c4.ctg.1	3993	356.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3102	3102	C	403	C	351	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	500	folP	852	852	100.0	folP.l15.c4.ctg.1	2086	72.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1258	1260	AGC	113;113;113	A;G;C,A	101;102;97,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1052	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	4134	76.3	1	SNP	p	S91F	0	.	.	271	273	TCC	1057	1059	TCC	94;96;96	T;C,A;C	85;89,1;87	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1052	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	4134	76.3	1	SNP	p	D95G	0	.	.	283	285	GAC	1069	1071	GAC	95;95;95	G;A,T;C	88;86,1;86	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1052	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	4134	76.3	1	SNP	p	D95N	0	.	.	283	285	GAC	1069	1071	GAC	95;95;95	G;A,T;C	88;86,1;86	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	468	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1823	76.7	0	.	p	.	0	A40P	NONSYN	118	120	GCC	725	727	CCC	104;104;104	C;C;C	90;92;93	.	.
mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888	1	1	539	468	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1823	76.7	1	SNP	p	G45D	0	.	.	133	135	GGC	740	742	GGC	101;102;101	G,C;G;C	93,1;96;96	mtrR.Neisseria_meningitidis_serogroup_A_Z2491_v1_01888:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1072	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3513	91.4	1	SNP	p	D86N	0	.	.	256	258	GAC	793	795	GAC	115;113;114	G;A;C	103;99;104	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1072	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3513	91.4	1	SNP	p	S87R	0	.	.	259	261	AGT	796	798	AGT	115;115;116	A;G;T	102;107;105	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1072	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3513	91.4	1	SNP	p	S87W	0	.	.	259	261	AGT	796	798	AGT	115;115;116	A;G;T	102;107;105	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1072	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3513	91.4	1	SNP	p	S87I	0	.	.	259	261	AGT	796	798	AGT	115;115;116	A;G;T	102;107;105	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1072	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3513	91.4	1	SNP	p	S88P	0	.	.	262	264	TCC	799	801	TCC	116;117;117	T;C,A;C	106;108,1;107	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	918	parE	1986	1986	100.0	parE.l15.c17.ctg.1	3343	82.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1971	1973	GGC	101;100;102	G;G;C,G	89;88;86,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1564	1566	GCA	96;96;96	G;C;A,C	85;87;88,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1567	1569	ATC	96;97;99	A;T;C	88;88;89	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1579	1581	GTG	101;100;102	G,A;T;G	90,1;87;92	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1579	1581	GTG	101;100;102	G,A;T;G	90,1;87;92	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2083	2085	ACC	101;101;100	A;C;C	94;97;95	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2137	2139	GCG	92;93;93	G;C,T,A;G,C	79;68,1,1;73,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2137	2139	GCG	92;93;93	G;C,T,A;G,C	79;68,1,1;73,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2260	2262	GGC	96;96;97	G;G;C	88;90;89	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2269	2271	GGC	97;97;98	G;G;C	90;88;91	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	776	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2994	77.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2287	2289	CCG	98;98;98	C;C,T;G	88;90,1;87	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1090	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3507	93.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1867	1869	CTG	117;117;119	C;T;G	106;106;109	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	540	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2403	67.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	872	872	C	103	C	91	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	179	90.71	porB1a.l15.c4.ctg.1	1513	15.1	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1359	1361	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	179	90.71	porB1a.l15.c4.ctg.1	1513	15.1	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1362	1364	AAT	4;4;4	A;A;T	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	179	90.71	porB1a.l15.c4.ctg.1	1513	15.1	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1374	1376	GTT	4;4;3	G;T;T	4;4;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	179	90.71	porB1a.l15.c4.ctg.1	1513	15.1	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1386	1388	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	179	90.71	porB1a.l15.c4.ctg.1	1513	15.1	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1409	1411	GTA	2;2;2	G;T;A	2;2;1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	76	porB1a	984	179	90.71	porB1a.l15.c4.ctg.1	1513	15.1	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1421	1421	G	2	G	2	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	1000	1002	CTT	112;111;112	C;T;T	99;97;96	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	1024	1026	GGA	112;112;111	G,T;G;A	100,1;104;100	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	1108	1110	GGT	110;110;109	G;G;T	103;102;102	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1162	1164	AGC	114;114;116	A;G;C	103;103;103	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1228	1228	T	116	T	104	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	1	SNP	p	G120K	0	.	.	358	360	GGT	955	957	GGT	111;112;112	G;G;T	106;106;102	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	1	SNP	p	A121D	0	.	.	361	363	GCC	958	960	GCC	112;113;113	G;C;C	101;102;103	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	668	porB1b	1035	1035	95.82	porB1b.l15.c4.ctg.1	1945	101.1	1	SNP	p	A121N	0	.	.	361	363	GCC	958	960	GCC	112;113;113	G;C;C	101;102;103	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1910	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5297	108.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2261	2263	AAT	119;119;119	A;A;T	109;113;109	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	326	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1287	75.1	1	SNP	p	V57M	1	.	.	169	171	ATG	666	668	ATG	131;130;131	A,C;T;G,T	113,1;112;117,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
